Company news

Immunovant, Inc. news in 2021

Immunovant, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

December 29, 2021

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

November 11, 2021

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

November 4, 2021

Immunovant to Participate in Roivant R&D Day 2021

September 26, 2021

Immunovant Appoints Renee Barnett as Chief Financial Officer

September 14, 2021

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

August 8, 2021

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

August 5, 2021

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

August 1, 2021

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

May 31, 2021

Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020

February 15, 2021

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

February 1, 2021

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

January 11, 2021

Calls in 2021

Decks in 2021